The significant revenue growth from commercialization is positive, but the widening loss and long timeline to TIGeR-PaC data (2027) suggest cash burn will continue. The $13 million cash runway appears sufficient, but investors should monitor commercial growth rate and trial enrollment progress as near-term catalysts.
Price Chart
Executive Summary
RenovoRx reported $1.1 million in revenue for 2025, its first full year of commercialization, up from $43,000 in 2024, driven by early adoption of its RenovoCath device at U.S. cancer centers. The company raised $9.2 million in net proceeds, bringing cash on hand to $13 million, and advanced its Phase III TIGeR-PaC trial, which is on track for final data in 2027. Despite growing revenue, the net loss widened to $11.2 million.
Key Financial Metrics
Key Facts
- 2025 revenue was $1.1 million (up from $43,000 in 2024), marking first full year of RenovoCath commercialization.
- Net loss increased to $11.2 million in 2025 from $8.8 million in 2024.
- Company raised $9.2 million in net proceeds via private placement, bringing total cash to $13 million as of March 2026.
- Phase III TIGeR-PaC trial has randomized 104 of 114 required patients; final data expected in 2027.
- 12 U.S. cancer centers are actively using RenovoCath, with 21 additional centers in evaluation or activation pipeline.
Financial Impact
Revenue grew over 2,500% YoY to $1.1 million, but operating losses expanded due to higher SG&A and R&D spending. $13 million in cash supports operations into 2027.
Risk Factors
- Long path to profitability given current burn rate and 2027 data readout timeline.
- Commercial adoption remains limited to 12 active centers; scalability of sales model is unproven.
- No revenue guidance provided for 2026, leaving growth expectations uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265014 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $1.27 | awaiting T+60 | — | $1.39 (+9.45%) |
Jul 29, 2026 12w ago | Press Release | $0.8981 $1.27 | ▲ +41.41% | ▲ +36.68% | $1.39 (+54.77%) |
Jul 2, 2026 16w ago | 8-K | $0.9201 $1.68 | ▼ −82.59% | ▼ −79.58% | $1.39 (−51.07%) |
May 26, 2026 22w ago | Press Release | $0.9160 $1.32 | ▲ +43.56% | ▲ +40.83% | $1.39 (+51.75%) |
May 19, 2026 23w ago | Press Release | $0.8060 $1.26 | ▲ +56.33% | ▲ +50.04% | $1.39 (+72.46%) |
May 15, 2026 23w ago | 10-K/A | $0.7830 $1.12 | ▲ +43.04% | ▲ +38.19% | $1.39 (+77.52%) |
May 14, 2026 23w ago | 8-K | $0.8200 $1.15 | ▲ +40.24% | ▲ +35.73% | $1.39 (+69.51%) |
Apr 29, 2026 25w ago | Press Release | $0.8310 $0.8653 | ▲ +4.13% | ▲ +0.02% | $1.39 (+67.27%) |
Apr 28, 2026 26w ago | EFFECT | $0.8400 $0.8545 | ▲ +1.73% | ▼ −2.26% | $1.39 (+65.48%) |
Apr 16, 2026 27w ago | S-3 | $1.00 $0.8500 | ▼ −15.00% | ▼ −21.14% | $1.39 (+39.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers